Free Trial
CVE:BCT

BriaCell Therapeutics (BCT) Stock Price, News & Analysis

BriaCell Therapeutics logo
C$10.60 -0.42 (-3.81%)
(As of 12/30/2021)

About BriaCell Therapeutics Stock (CVE:BCT)

Key Stats

Today's Range
C$10.60
C$11.07
50-Day Range
C$10.60
C$10.60
52-Week Range
C$3.50
C$15.75
Volume
3,402 shs
Average Volume
12,671 shs
Market Capitalization
C$168.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$15.00
Consensus Rating
N/A

Company Overview

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Receive BCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCT Stock News Headlines

BriaCell Shows Promise in Cancer Immunotherapy Advances
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
BriaCell’s Promising Breast Cancer Study Results
BCT:CA BriaCell Therapeutics Corp.
See More Headlines

BCT Stock Analysis - Frequently Asked Questions

BriaCell Therapeutics' stock was trading at C$10.60 at the start of the year. Since then, BCT shares have increased by 0.0% and is now trading at C$10.60.
View the best growth stocks for 2024 here
.

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), BMO MSCI India ESG Leaders Index ETF (ZID), Athersys (ATHX), Anavex Life Sciences (AVXL), Gene Biotherapeutics (CRXM) and Inovio Pharmaceuticals (INO).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$15.00
High Stock Price Target
C$15.00
Low Stock Price Target
C$15.00
Potential Upside/Downside
+41.5%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$3.34 per share
Book Value
C$3.60 per share

Miscellaneous

Free Float
N/A
Market Cap
C$168.68 million
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (CVE:BCT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners